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Review Article
Recurrent urinary tract infections in females
Raheela Mohsin,1 Khurram Mutahir Siddiqui2

Department of Gynecology and Obstetrics,1 Section of Urology, Department of Surgery,2 Aga Khan University Hospital, Karachi.

Abstract

Uncomplicated Urinary tract infections are common in
adult women across the entire age spectrum, with mean annual
incidence of 15% and 10% in those aged 15-39 and 40-79
years, respectively. Urinary tract infection (UTI), with its
diverse clinical syndromes and affected host groups, remains
one of the most common but widejly misunderstood and
challenging infectious diseases encountered in clinical
practice. Recurrent urinary tract infections (UTIs) present a
significant problem for women and a challenge for the doctors
who care for them. The diagnosis of uncomplicated UTI can
be achieved best by a thorough assessment of patient
symptoms with or without the addition of a urine dipstick test.
Treatment should be based on the most recent guidelines,
taking into account resistance patterns in the local community.
The patient who suffers from recurrent UTIs can be treated
safely and effectively with continuous antibiotic prophylaxis,
post-coital therapy, or self-initiated treatment. This review
article covers the latest trends in the management of recurrent
UTI among women. Further research is needed regarding
rapid diagnosis of UTI, accurate presumptive identification of
patients with resistant pathogens, and development of new
antimicrobials for drug-resistant UTI.

Introduction

Treatment of recurrent urinary tract infections (UTI) in
female is one of the most difficult challenges for the
physicians, affecting about 25% of women with a history of
isolated urinary tract infection.1 It is certainly bothersome for
the patient and the sequelae may not only cause morbidity but
in high risk patients carries a significant risk of mortality.
When bacterial virulence increases or host defense
mechanisms decrease, bacterial inoculation, colonization, and
infection of the urinary tract occurs. Careful diagnosis and
treatment results in successful resolution of infections in most
instances. Treatment of recurrent urinary tract infection
requires understanding of the pathogenesis of UTI and the role
of host and bacterial factors.2 Only with insight into this
process, we can improve our ability to identify patients at risk
and reduce morbidity.
The urinary tract is normally sterile; bacteria that
generally ascend from the peri-anal area reservoir may cause
UTIs. Bacteria in the urinary tract may remain asymptomatic
or cause irritative symptoms such as frequency and urgency. If
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untreated, the infection may ascend to the upper urinary tract
and produce fever, chills, and flank pain. Bacterial entry into
the blood stream is associated with severe morbidity,
including sepsis and death.3

An ideal antimicrobial agent should be orally
administrable and able to achieve high urinary and tissue
levels without producing any nephrotoxicity. Developments in
pharmacology have lead to introduction of drugs which have
significantly reduced the need for hospitalization for severe
infection. Shorter-course therapy and prophylactic
antimicrobial agents have reduced the morbidity and cost
associated with recurrent UTI in women.
Although the vast majority of patients respond
promptly and are cured by therapy, early identification and
treatment of patients with complicated infections that place
them at significant risk remains a clinical challenge.

Definition:

Recurrent urinary tract infection (RUTI) is defined as
three episodes of urinary tract infection (UTI) with 3 positive
urine cultures in the previous 12 months or two episodes in the
last six months.4

Risk Factors:

According to Cohort and case controlled studies by
Hooton et al risk factors associated with recurrent UTI in
sexually active premenopausal women are the symptom
proximity to sexual intercourse, use of spermicides, the age of
first UTI (less than 15 years of age indicates a greater risk of
RUTI) and history of UTI in the mother is suggesting that
genetic /long term environmental exposures might predispose
to this condition.5 In postmenopausal women Utero-vaginal
prolapse, urinary incontinence and post void residual urine are
important risk factors.
Infection with multi-resistant pathogens is more likely
to occur in complicated UTI. The risk is increased with
obstruction or any factor that causes urinary stasis, for
example urolithiasis, malignancy, renal cyst, neurogenic
bladder, or urethral diverticulum. The most common factors
include an indwelling catheter, ureteric stent, or nephrostomy
tube. Some medical conditions e.g. diabetes mellitus,
pregnancy, renal failure, renal transplantation, and
immunosuppression facilitates entry of uropathogens by
bypassing normal host defenses. Diabetes mellitus has been
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shown to have a two- to threefold increase in frequency of
RUTI.6

Diagnosis:

Diagnosis is usually made with the history and 3
positive urinary cultures with in the preceding 12 months.
Irritative voiding symptoms are common among 25-30 % of
women with recurrent UTI.7 Among women with irritative
voiding symptoms, clinical symptoms can help to identify
women with recurrent urinary tract infections at the initial
presentation even if urine culture reports are not available.
Causes of irritative voiding symptoms include urethral
syndrome, interstitial cystitis, and recurrent urinary tract
infections. It is often difficult to identify women with recurrent
urinary tract infections at their initial presentation in the office
because urine culture reports may not be available. Generally
the women with RUTI in our country are treated by general
practitioners and the repeated use of antibiotics leads to
resistance and a proper diagnosis is never established. A recent
retrospective case controlled study differentiated between
clinical symptoms predictive of recurrent UTI and irritative
voiding symptoms. Women in the recurrent urinary tract
infection group were significantly more likely to report
symptoms after intercourse, a prior history of pyelonephritis,
and prompt resolution of symptoms after taking antibiotics
than women with irritative voiding symptoms
(dysuria,urgency,and/or frequency).8 Women in the recurrent
urinary tract infection group were significantly less likely to
report nocturia and persistence of symptoms between episodes
of urinary tract infection than women with irritative voiding
symptoms. For women reporting irritative voiding symptoms
between perceived episodes of urinary tract infection or
nocturia suggests a non-infectious cause to their symptoms
and they may be at higher risk for voiding dysfunction or
reduced bladder compliance as seen in interstitial cystitis,
urethral syndrome, or detrusor overactivity.These women
require cystoscopy and/or cystometrogram and in 80% of
women significant abnormalities were detected during
cystoscopy with most over 50 years.9

Classification:

Uncomplicated UTIs occur in patients with urinary
tracts that are normal from both a structural and functional
perspective. Most women in outpatient setting present
uncomplicated UTIs and respond promptly to short term,
inexpensive oral antimicrobial therapy.
Complicated or Recurrent UTIs occur in patients with
any anatomic, structural or functional abnormality that
compromises therapy. Fever and chills are common along
with other systemic symptoms and broad spectrum therapy is
required.

Infections are further characterized into the
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following categories:

Isolated infection: Isolated infections are either initial
episodes of infection or are separated by six months from
other episodes of infections, 25-40% of women aged 30-40
years present with isolated infection

Unresolved infection: Unresolved infections occur in
patients with whom therapy has been unsuccessful due to
bacterial resistance to the drug selected for treatment or
bacteriuria caused by two different species with mutually
exclusive susceptibilities. Another less common cause is
presence of giant stag horn calculi and azotaemia.

Re-infection: Re-infection refers to a new infection,
i.e. the urine shows no growth after the previous infection, but
the same organism is re-grown 2 weeks after treatment, or a
different strain is grown at any time.10 These represent 95% of
recurrent UTIs in women. Bacterial persistence occurs when
therapy is subverted by sequestration of bacteria in a site that
is protected from the drug. Recognizing bacterial persistence
is important because the cause must be removed to achieve
sterilization. Common correctable urologic abnormalities that
can cause bacterial persistence include infected stones, uretral
duplication and ectopic ureters, foreign bodies, urethral
diverticula and infected Para-urethral glands.
A relapse is a UTI caused by the same bacterial strain
from a focus inside the urinary tract within 2 weeks of
treatment However, it is frequently impossible to distinguish a
re-infection from a relapse.11

Pathogenesis:

The pathogenesis of recurrent UTI is assumed to be the
same as with sporadic infection. The infecting bacteria in both
recurrent UTIs and a de novo acute infection have been
thought to originate from an extra urinary location. Most
uropathogens originate in the rectal flora, colonize the periurethral area and urethra, and ascend to the bladder. Increasing
evidence suggests that alteration of the normal vaginal flora,
especially loss of H2O2-producing lactobacilli, may
predispose women to introital colonization with Uro-Pathogen
Escherichi Coli (UPEC), which is responsible for 85% of
infections in ambulatory patients and 50% of nosocomial
infections.12 Although the vast majority of UPEC are cleared
by host defenses within a few days, small clusters of
intracellular bacteria have occasionally been observed to
persist for months in an antibiotic-insensitive state.13 It has
been shown in a murine model of UTI that uropathogenic
Escherichia coli (UPEC) established quiescent intracellular
reservoirs (QIRs) in endosomes within the urinary bladder
epithelium.14 Depending on the integrity of the urothelial
barriers at the time of initial infection, these QIRs were
established within terminally differentiated superficial facet
cells and/or underlying transitional epithelial cells. Treatment
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of infected bladders harbouring facet epithelial cell barrier,
invading bacteria also face a chemical barrier: the complex
network of proteoglycans/glycosaminoglycans (GAG layer)
that is woven into the urothelium and is known to act as an
antimicrobial adherence factor. Normal physiological changes
in levels of GAGs may render bladders more vulnerable to
invasion by bacteria. Even in healthy young women with
presumably unperturbed epithelia, bladder GAG levels may
vary during the normal menstrual cycle. Furthermore, certain
UPEC strains may contain virulence factors that allow the
bacteria to penetrate into the transitional cells and form QIRs.
Establishment of QIRs throughout the underlying transitional
epithelium may predispose an individual to an increased
likelihood of recurrence and may account for some of the
frequent same-strain recurrences that are seen clinically
despite appropriate antibiotic therapy.

Counseling and Treatment:

A woman suffering from uncomplicated UTI should
be informed about the possible recurrences and the
relationship between UTI and sexual intercourse. Asking a
patient about her own conception of the illness may (as in
many general practice consultations) improve mutual
understanding. The basic treatment begins with antimicrobial
therapy and there are many choices available but one must
understands the principles of antimicrobial therapy.

Principles of Antimicrobial Therapy:

The objective of antimicrobial therapy is to eliminate
the bacterial growth in the urinary tract utilizing antimicrobial
agent which is efficacious, safe, and cost effective. The dose
duration should be patient friendly to ensure compliance and
the therapy should be prescribed only for the least possible
time to decrease the resistance emerging from excessive
utilization

The resolution of infection is dependant on the
susceptibility of the bacteria to the concentration of the
antimicrobial agent achieved in the urine. Antimicrobial agent
should ultimately eliminate bacterial growth in the urinary
tract. This can occur within hours if the proper antimicrobial
agent is used which is able to achieve levels in the urine and
the duration that this level remains above the minimal
inhibitory concentration of the infecting organism.15 An
effective antimicrobial agent usually achieves minimal
inhibitory concentration both in the serum and urine of healthy
adults, the urinary levels are often many folds greater than the
serum levels. However the serum levels are critical in patients
with uro-sepsis and urinary infections involving renal
parenchyma.16

Patients with renal insufficiency and obstructive
uropathy require dose modifications. Other patient
factors like age, potential pregnancy or lactation should
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also be considered.17

The use of prophylactic antibiotics for six to 12 months
is effective in reducing the number of recurrent UTI s but no
antibiotic is significantly better than others at decreasing the
number of UTIs. Postcoital prophylaxis is as effective as daily
prophylaxis in young women but it should be offered to
women who have UTI associated with sexual intercourse.
Limited evidence suggests that weekly prophylaxis is better
than monthly prophylaxis.18

Adjuvant Measures:

Adjuvant measures for treatment or against recurrence
and prophylaxis are often asked for by patients or
recommended by GPs, based on risk factors present in a
patient. Most have not been evaluated in randomized trials or
prospective studies.
Sufficient fluid intake (at least two liters per day) and
regular voiding is commonly believed to have a 'flushing'
effect on the urinary tract; bacterial proliferation might be
hindered, owing to a shorter retention of urine in the patient's
bladder. However, no trials of the effect of high fluid intake on
UTI could be found in literature.

Micturition after sexual intercourse is supposed to
rinse bacteria from the bladder and thus prevent UTI.19 Since
damage to the physiological vaginal flora facilitates UTI,
exaggerated genital 'hygiene' (deodorant sprays, vaginal
lotions or douching, etc) should be avoided (recommendation
grade A).20 If possible, other methods of contraception should
be used in preference to spermicidal or diaphragms
(recommendation grade A). For frequently recurring UTI,
different therapeutic/prophylactic regimens can be useful; if
UTI episodes occur frequently after sexual intercourse, and if
post-coital voiding is not successful, 100mg trimethoprim can
be taken after sexual intercourse (recommendation grade A).21
Otherwise, therapy with 50 mg trimethoprim daily or 50 mg
nitrofurantoin daily for six months is effective and well
tolerated (recommendation grade A). Should frequent UTI
still occur after six months, this treatment can be continued for
several years if necessary.

In postmenopausal women, local substitution of
oestrogen (for example, vaginal cream containing oestrogens)
improves the trophic of the vaginal mucosa and has been
shown to reduce the frequency of UTI (recommendation grade
A).Based on only two studies in a systemic review of
Cochrane database22 which compared vaginal oestrogens to
placebo, it has been proved that vaginal oestrogens reduced
the number of UTIs in postmenopausal women with RUTI,
however this varied according to the type of oestrogen used
and the treatment duration.
Cranberry products have been advocated in America.
Cranberries (usually as cranberry juice) have been used to
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prevent urinary tract infections (UTIs). Cranberries contain a
substance that can prevent bacteria from sticking on the walls
of the bladder. This may help prevent bladder and other
urinary tract infections. The Cochrane systemic review shows
the evidence from four RCTs (randomized controlled trials)
that cranberry product can be effective in reducing UTIs.23

Methenamine salts are often used as an alternative to
antibiotics for the prevention of urinary tract infection (UTI).
Methenamine salts act via the production of formaldehyde
from hexamine, which in turn acts as a bacteriostatic agent.24
It is uncertain whether urinary acidification and the direct
bacteriostatic effect of hippuric acid contribute significantly to
its action.25 Methenamine salts are well tolerated and adverse
effects, including minor gastrointestinal upsets, dysuria,
abdominal cramps, anorexia, rash and stomatitis, are generally
mild .Methenamine hippurate appears to be ineffective when
used in spinal cord injured patients with neuropathic bladder.26
The rate of adverse events reported by the studies was low,
which suggests that current usage is unlikely to be causing
significant harm.27
Cooling of the feet has been shown to promote an
acute episode in patients prone to recurrent UTI, they should
try to avoid getting cold (recommendation grade B).28
Acupuncture has been shown to be successful in
preventing frequent UTI episodes in one randomized, singleblind controlled trial in 67 patients with recurrent UTI.29

Physician approach for patient with recurrent
urinary tract infection:

The approach in the management of recurrent urinary
tract infections is out lined in the Figure. We need to adequately
treat an episode of infection and after the completion should
document complete eradication with a urine culture and if
infection reoccurs or persists then imaging is required. An
ultrasound KUB with pre and post void bladder volumes is
vital and may reveal a stone or anatomical abnormality such as
hydronephrosis and hyroureter which may need further
evaluation by an Intravenous urogram (IVU) to look for a
ureteric stone or congenital anomalies like pelviureteric
junction obstruction or ureteric strictures. Some times extra
mural obstruction from adjacent organs like ovarian or uterine
pathologies may result in hydroureter and can present as
recurrent infections. If no obstruction is seen in the IVU but
hydroureter is present, a micturating cystourethrogram may be
done to look for vesicoureteric reflux.
If the ultrasound does not reveal any upper tract
abnormality, the bladder volumes would still help us in getting
to the cause of infections. A large post void residue may be a
focus of recurrent infections and if left untreated would result
in damage to the kidneys. If the post void residue is more than
100 cc, a uroflowmetery is advised to rule out bladder out flow
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Figure: Flow chart for treating recurrent urinary tract infection by physicians.

obstruction from urethral stenosis, however if there is no
obstruction on uroflowmetery, it is crucial to do urodynamic
to assess the contractile capacity of the detrusor muscle and in
case there is hypotonic bladder it may require clean
intermittent self catheterization, a strategy often required in
poorly controlled diabetic with hypotonic bladder.
If a risk factor in certain cases is not identified, a
cystoscopy may be performed to rule our any mucosal lesion
or foreign body in the bladder.

If no risk factors are identified and the urinary tract
infections recur, prophylactic antibiotics are recommended as
described earlier.30

Conclusion

One in four women with UTI will suffer from
recurrences, in healthy, young or pre-menopausal women the
most common risk factor is sexual intercourse. E. coli is the
most commonly isolated uropathogen and the basic treatment
begins with antimicrobial therapy. Investigations must aim not
only to verify the diagnosis of RUTI but also to find any
possible cause of the recurrence but in the majority of women
with recurrent uncomplicated cystitis there is no anatomical or
functional abnormality of the urinary tract and, therefore
advanced radiological imaging studies are not required.
Management of most complicated infections depends on
clinical experience and resources at individual institutions
rather than on evidence based guidelines. Prevention include
J Pak Med Assoc

avoiding use of deodorant sprays, vaginal lotions or douching.
If possible, other methods of contraception should be used in
preference to spermicidal, diaphragms or condoms. Although
many approaches have not been adequately tested in studies
but it is reasonable to use cranberry juice, methanamine salts
and estrogen cream in postmenopausal women as a way of
minimizing antibiotic exposure. The use of prophylactic
antibiotics for six to 12 months is effective in reducing the
number of recurrent UTIs but no antibiotic is significantly
better than others at decreasing the number UTIs.
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